Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Sali... ( Exclusive prescription spray product ...)

Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product

Date:12/11/2008

Exclusive prescription spray product to treat Xerostomia will compete in $1 Billion US Market

RED BANK, N.J., Dec. 11 /PRNewswire/ -- Bi-Coastal Pharmaceutical Corp. announced today that it has acquired the US marketing rights to Aquoral(TM) artificial saliva. Aquoral(TM) is a lipid based artificial saliva spray product that is currently the only Prescription spray product marketed in the United States to treat Xerostomia. The total US market for products treating Xerostomia was estimated at $1 Billion in 2007. The product is sold in a 40ml (1.4 fl. oz.) spray bottle that if used as directed is a 2 month supply. Aquoral(TM) has already received overwhelming acceptance by physicians as well as patients suffering with Xerostomia. The sales and marketing of Aquoral(TM) will begin by Bi-Coastal to the Pharmaceutical trade channels immediately.

Bi-Coastal Pharmaceutical Corp. is a leading Sales, Marketing and Consulting company founded in 1982 and based in Red Bank, New Jersey. Since 2001, Bi-Coastal has secured product sales in excess of $650 Million. Bi-Coastal is currently finalizing its multi-faceted sales and marketing plans for Aquoral(TM) that will include an aggressive trade and physician advertising campaign, telemarketing, direct mail and other programs to physicians as well as a detail sales force initially targeting the Dental, Oncology, Rheumatology and Managed Care markets.

Ralph Massa, Jr., Bi-Coastal Pharmaceutical Corp.'s President and Chief Operating Officer stated the following, "I am pleased to announce the acquisition of Aquoral(TM) and confident that we will achieve significant sales levels well within the first year of marketing the product. Aquoral(TM) will soon be a trusted and proven household name to treat Xerostomia as it is an extremely effective and easy to use product with no known adverse effects. We look forward to the official re-launch of Aquoral(TM) to the trade at t
'/>"/>

SOURCE Bi-Coastal Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related medicine news :

1. AlphaDetail, Inc. Continues Bi-coastal Expansion
2. Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities
3. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
4. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
11. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference

Post Your Comments:

(Date:12/1/2009)...SHENZHEN, China, Dec. 1 /PRNewswire-Asia-FirstCall...PD ) ("Nepstar" or "the Company"), the largest ret...f directly operated stores,today announced its un...ded,September 30, 2009. ,, Financial High...ted a voting rights assignment agreement,which as...

(Date:12/1/2009)...ltrasound with elastography can help differentiate...ording to a study presented today at the annual me... (RSNA). , "High-frequency ultrasound with elast...y of skin cancer diagnosis," said lead author Elio... of Radiology at the University of Maryland School...

(Date:12/1/2009)... as a child could lead to early degeneration in th...he annual meeting of the Radiological Society of N...to show an association between increased body mass...said the study,s lead author, Judah G. Burns, M.D....ren,s Hospital at Montefiore in New York City. ,...

(Date:11/30/2009)...ast Coast Fertility is attempting to dispel the no...ments and send patients home pregnant with multipl...e patient, their priority is health and safety. I...e births can put on a country’s healthcare s...ber 30, 2009 -- Many patients and doctors in the U...

(Date:11/30/2009)... A study using functional magnetic...on revealed that adults who were exposed to lead a...ts were presented today at the annual meeting of t..., "What we have found is that no region of the ...y,s lead author, Kim Cecil, Ph.D., imaging scienti...

[0] China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009 [0] Special ultrasound accurately identifies skin cancer [0] Overweight children may develop back pain and spinal abnormalities [0] East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program [0] Childhood Lead Exposure Causes Permanent Brain Damage

...e Online Charity Auction of Designer, Handbags f...e Ovarian Cancer Research...ding premium,appliance brand, and Kelly Ripa have ...t ovarian cancer. The bags,were featured in "Kelly...

...eatly reduced if parents quit, LONDON, May 28 If...ows that a child,s odds of daily smoking are,reduc...h parents continue,to smoke. And if both parents w...ldren who start smoking.(2), As global leaders in...

...eive $10,000 scholarships to help with,escalating ...fort to promote,diversity and help with the rapidl...edical Association (AMA) Foundation has presented ...ise for the future,among first- or second-year med...

...s of $35 Cost Per Metric Ton of CO2 Indica...PITTSBURGH, May 28 As recent judicial, political ...ve the United States toward a,mandatory price for ...fects of establishing such a cost. The research,pu...

... and PainSmart Infusion Pumps Undergo,Immediate Te...tion,Overinfusion, PLYMOUTH MEETING, Pa., May 28 ...ndent, nonprofit organization that,researches the ...esources_pages_default.aspx, ,recommending immedia...

... remarks by,Attorney General Michael B. Mukasey on...care fraud nationwide:, Thank you, and good after...e importance of the job that the Justice Departmen...or your hard,work., Our nation,s health care syst...

Other Medicine News:Health News:Coveting the Latest Clutch? Bid on a Bag and Help Fight Ovarian Cancer 2 Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 2 Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 3 Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 4 Health News:AMA Foundation Names Minority Scholars Award Recipients 2 Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 2 Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 3 Health News:ECRI Institute Issues Priority Alert About Two Infusion Pumps 2 Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 2 Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 3

Coveting the Latest Clutch? Bid on a Bag and Help Fight Ovarian Cancer Parents: Quit Smoking and Your Children Are Less Likely to Smoke AMA Foundation Names Minority Scholars Award Recipients Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows ECRI Institute Issues Priority Alert About Two Infusion Pumps Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide

(Date:12/1/2009)... An expert from PAREXEL I...ng global biopharmaceutical services provider, wil... to drug development in Asia at the Partnerships i...eld December 1-3, 2009 at the Intercontinental Hot...rence, which is focused on maximizing efficiency a...

(Date:11/30/2009)...ewswire-FirstCall/ -- DATATRAK International, Inc....focused on global eClinical solutions for the clin...rma Focus AG (PFC) has joined its CRO Connect Prog... DATATRAK,s CRO partner training and offer its cli... addition, PFC will also have access to Partner pr...

(Date:11/30/2009)...30 Covance Inc. (NYSE: ... Piper Jaffray 21st Annual Health Care Conference ... Investors may access a live webcast of the presen... and download any necessary software, please log o...rs in Princeton, New Jersey, is one of the world,s...

Breaking Medicine Technology:PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2 PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3 PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4 PFC Pharma Joins DATATRAK's CRO Connect Program 2 PFC Pharma Joins DATATRAK's CRO Connect Program 3 PFC Pharma Joins DATATRAK's CRO Connect Program 4 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 12392 1 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 12392 2 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 12392 3 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 12392 4 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 12392 5 Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 1 Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 2 Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 3 Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 1 Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 2 Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 3

[0] PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference [0] PFC Pharma Joins DATATRAK's CRO Connect Program [0] Covance to Present at Piper Jaffray 21st Annual Health Care Conference

...nd Achieves All Key Endpoints for Both Efficacy an...ire-FirstCall/ --,Indevus Pharmaceuticals, Inc. to...rmacokinetic trial for NEBIDO (testosterone,undeca...rapy under,development for the treatment of male h...Schering Pharma AG, Germany. The data,from the rec...

...en(TM) is evaluating zonisamide SR as a novel comp...DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Ore... company focused on the,treatment of central nervo...ty, today announced results from a Phase I trial e..., proprietary,sustained-release (SR) formulation ...

Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2 Indevus Reports Positive Data From Phase III NEBIDO Trial 3 Indevus Reports Positive Data From Phase III NEBIDO Trial 4 Indevus Reports Positive Data From Phase III NEBIDO Trial 5 Indevus Reports Positive Data From Phase III NEBIDO Trial 6 OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2 OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3 OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4

Indevus Reports Positive Data From Phase III NEBIDO Trial OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation

...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...

Medicine Products:

Marsh gas, Whole Blood Maprotiline Quantitation Manganese, Urine Malaria Antibodies, IgG

Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Sali...( Exclusive prescription spray product ...),Health